Biocon Limited successfully completed a Qualified Institutions Placement (QIP), raising ₹4,150 crore (~USD 460 million). The proceeds will primarily fund the acquisition of Viatris’ stake in Biocon Biologics Limited and debt repayment. The QIP attracted strong interest from both domestic and international investors, demonstrating confidence in Biocon’s growth prospects. The integration of Biocon Biologics is expected to be completed by March 31, 2026.
Successful Equity Fundraise
On January 14, 2026, Biocon Limited announced the successful completion of a Qualified Institutions Placement (QIP), raising ₹4,150 crore (~USD 460 million). The QIP involved the issuance of 112,664,585 equity shares at a price of ₹368.35 per share.
Use of Proceeds
The funds raised will be primarily used for the following:
Investor Interest
The QIP attracted strong investor interest from a diverse range of domestic and international participants. The offering witnessed participation from 39 investors, including leading financial institutions such as SBI Mutual Fund, ICICI Prudential Mutual Fund, and Mirae Asset Mutual Fund.
Strategic Rationale
The acquisition of Viatris’ stake in Biocon Biologics will make Biocon Biologics a wholly owned subsidiary of Biocon Limited. This integration marks a significant step in Biocon’s journey to lead in the therapeutic areas of diabetes, oncology, and immunology. The integration process is expected to be completed no later than March 31, 2026.
Source: BSE
